Pharmaceuticals
NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc 'Melania'
NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + First Lady Melania Tr...
2026-01-28 21:55
7856
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
* Ranked in the top one percent among more than 150,000 companies assessed globally * Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract developm...
2026-01-28 20:00
8976
Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Con...
2026-01-28 19:39
6662
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obes...
2026-01-28 12:08
5549
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from base...
2026-01-28 10:45
7963
Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0
BOSTON and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy,HKEY-AIRxTM1.0 designed to address one of the most persistent problems facing biotech leadership: w...
2026-01-27 22:00
7184
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center...
2026-01-27 22:00
9056
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC)....
2026-01-27 21:00
9709
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting. Skyhawk also ann...
2026-01-27 21:00
8813
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
* Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. * License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. *...
2026-01-27 18:40
7194
Libevitug Approved in China as First-in-Class Treatment for Hepatitis D
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug...
2026-01-27 16:18
6042
Libevitug Approved in China as First-in-Class Hepatitis D Treatment
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a hum...
2026-01-27 16:15
6590
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
* Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. * Growth over the financial year was driven by increased sales in oncology, particularly in the United States. * Several partnership agreements in oncology and neurology strengthen the Group's R&D portfoli...
2026-01-27 16:00
5018
Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease
SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive p...
2026-01-27 10:13
7421
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology
SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026), independently developed by the ...
2026-01-27 09:58
6607
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...
2026-01-27 08:00
8473
BIOSeedin Winter Innovation Partnering Summit：J.P.Morgan Spotlight
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- To enable Chinese innovative pharmaceutical companies to more efficiently connect with international resources, bioSeedin, a platform facilitating cooperation in innovative drug assets, hosted the BIOSeedin Winter Innovation Partnering Summit inSan Fra...
2026-01-26 22:00
7539
Gu Sheng Tang Donates S$1.06 Million to NTU Singapore to Advance Traditional Chinese Medicine Research and Education in Singapore
SINGAPORE, Jan. 26, 2026 /PRNewswire/ -- Leading Traditional Chinese Medicine (TCM) healthcare group Gu Sheng Tang TCM and Nanyang Technological University, Singapore (NTU Singapore) officially launched theGu Sheng Tang Traditional Chinese Medicine Education and Research Programme today. As part ...
2026-01-26 18:00
5486
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and auto...
2026-01-26 17:35
16164
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Developm...
2026-01-26 15:00
11703
Week's Top Stories
Most Reposted
Vietnam Explores Sustainable Aviation Fuel Development at International Conference in Hanoi
[Picked up by 301 media titles]
2026-06-25 14:33
MetaOptics Begins Shipment of Metalens Smartphone and AI Smart Glasses to European and Japanese Customers for Evaluation
[Picked up by 300 media titles]
2026-06-26 18:11IPD and ABB Help Power Sustainable Operations at New Sydney Fish Market
[Picked up by 298 media titles]
2026-06-22 17:40
SPHERE AX Partners with U.S. AI Semiconductor Company Blaize at the National Assembly
[Picked up by 293 media titles]
2026-06-24 18:00
BELLUSTAR TOKYO Ranked No. 10 Among Japan's Best City Hotels in Prestigious Award Chosen by Asia-Pacific Travelers
[Picked up by 290 media titles]
2026-06-24 12:00
Most Read
Korean Skincare Brand Meditherapy Tops Amazon U.S. Facial Serums, Breaking Into Beauty Best Sellers Top 20
2026-06-26 21:00
3191
National Book Store Partners with Anchanto to accelerate success across Online Channels & 260+ Retail Locations
2026-06-23 08:00
3120
IBM and OpenAI Bring Frontier AI to Cyber Defense--Helping Enterprises Keep Pace with Machine-Speed Threats
2026-06-23 05:18
2883
